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vasodilatation (P8.03) and resulted in higher plasma t-PA antigen and activity concen- 
trations during bradykinin Infusion (11.3+0.8 vs 6.6~0.5 ng/mL and 16.5t3.9 vs 6.6k2.0 
IU/mL at peak bradykinin dose: PcO.002) and a doubling of estimated net t-PA release 
(PcO.05). Conclusion: Intra-arterial TNF-a causes an acute local vascular inflammation 
associated with a substantial and sustained increase in local t-PA and IL-6 release. TNF- 
a also impairs endothelium-dependent vasomotion and augments acute endothelial t-PA 
release. These findings indicate that TNF-a has potentially adverse and beneficial effects 
on endothelial and vascular function. 
245 p.m. 
856-4 iNOS Is a Mediator of Increased Arterial lntimal 
Thickening Induced by Passive Cigarette Smoke 
Exposure in Mica 
Takeo Anazawa, Paul C. Dimayuga, Hongyan Li, Previn de Silva, Juliana Yano, Kuang- 
Yuh Chyu, Prediman K. Shah, Bojan Cercek, Cedars-Sinai Medical Center, Los Angeles, 
CA 
Background: Active and paswe smoking was associated with increased intimal/medial 
thickening in the Atherosclerosis Risk In Communities study, but molecular mechanisms 
contributing to this risk are incompletely understood. We evaluated the effect of passive 
smoke on arterial response to injury, and the potential role of iNOS gene in smoking 
induced effects on the arterial wall using iNOS -/- mice. 
Methods: Vascular injury was induced by placing a cuff around the right carotid attery. 
Wild type mice and iNOS -I- mice of the same background were exposed to passive 
smoke (1 agarettelday) or filtered room air. Expression of iNOS and PCNA in the arterial 
wall 3 days after injury was determined by immunostaining. Nitrate and nitrite (NOx) level 
3 days after injury was measured by Griess reaction. lntimal thickening was measured 21 
days after injury. 
Results: iNOS expression in wld type mice exposed to passive smoke increased com- 
pared to mice exposed to room air, and was not detected in iNOS -I- mice. lntimal thick- 
ening in iNOS-i- mice exposed to passive smoke was profoundly reduced compared to 
wld type mice exposed to passive smoke (Table). 
Medial areas were similar in all groups of mice. 
Conclusion: Our results suggest that iNOS expression is a key mediator in the aug- 
mented response to injury an mice exposed to cigarette smoke. iNOS may mediate vaso- 
occlusive effects of exposure to cigarette smoke. 
Table: 
Groups 
PCNA 
positive 
nuclei 
Wild-type + Wild-type + iNOS -/- mice + iNOS -I- mice + 
Room air Passive smoke Room air Passive smoke 
6.1 i2.7 ND 4.0 24.0 (Il=3) 
(Il=5) 
15.725.2 ” 
(rl=5) 
NOx level 22.3~ 7.3 39.1+ 12.8” 14.3 26.6” 12.5 + 6.6 (n=6) 
(lw (n=6) (n=5) @=6) 
lntimal Area 9.2 -+ 7.5 23.3+ 12.9’” 5.5i4.7” 2.1 + 1.6 (n=5) 
(m&x 16) (n=6) (ll=5) (ll=5) 
#p<O.O5 vs iNOS -I- +Passive smoke, ‘~~0.05 vs Wild-type+Room air, @I ~~0.05 vs 
Wild-type+Passive smoke; ANOVA 
3:oo p.m. 
856-5 Cardiovascular Effects of the Endogenous Nitric Oxide 
Synthase Inhibitor Asymmetric Dimathylarginina 
(ADMA) and Evidence for ADMA Metabolism in Humans 
In Vivo 
Vinod Achan Michael Broadhead. Mohammed Malaki. James Leiper. Raymond -3 
MacAllister. Patrick Valiance, University College London, London, Untted Kingdom 
BACKGROUND: Plasma levels of an endogenous NOS inhibitor, asymmetric dimethy- 
latginine (ADMA), are elevated in chronic renal failure, hypertension, and atherosclero- 
sis. ADMA levels are also significantly raised in patients with chronic heart failure (CHF) 
and in animals with CHF induced by coronary artery ligation or rapid pacing. Despite 
these obsewations the cardiovascular effects of a systemic increase in ADMA have not 
been studied in humans. METHODS: In a randomised, double-blind, placebo-controlled 
study using healthy male volunteers, we compared the effects of intravenous low dose 
ADMA and placebo on heart rate, blood pressure, cardiac output and systemic vascular 
resistance (SVR) at rest and during exercise. We also tested the hypothesis that ADMA 
IS metabolised extensively in humans in viva by a family of dimethylarginine dimethylami- 
nohydrolase (DDAH) enzymes. RESULTS: Low dose ADMA reduced heart rate by a 
maximum of 9.2+1.4% from 58.9k2.0 beats per min (PcO.OOl), and reduced cardiac out- 
put by a maximum of 14&1.2% from 4.4+0.3 Umin (PcO.001). ADMA also increased 
mean blood pressure by a maximum of 6.0*1.2% from E&6&3.4 mm Hg (PcO.CQS), and 
increased SVR by a maximum of 23.7t2.1% from 1639.0*91.6 dynes.s.cm-5 (P<O.OOl). 
Handgrip exercise Increased cardiac output in control subjects by a maximum of 
96.8+23.3%. In contrast, those subjects given ADMA increased their cardiac output by 
35.3+10.6% during exercise, representing a significant reduction in the cardiac response 
to exercise (PcO.05). DDAHs metabolise ADMA to citrulline and dimethylamine (DMA). 
Urinary DMA:Cr ratios significantly increased from 1.26kO.32 to 2.73kO.59 following 
ADMA injection (PcO.01). We estimate from this that humans generate approximately 
300umol of ADMA per day, of which approximately 250umol is metabolised by DDAHs. 
CONCLUSIONS: This study defines the cardiovascular effects of a systemic increase in 
ADMA in humans. These are similar to changes seen in diseases associated with ADMA 
accumulation, suggesting that ADMA could directly contribute to their pathogenesis. 
Finally, our data also indicate that ADMA is metabolised by DDAHs extensively in 
humans in viva. 
3:15 pm. 
856-6 Levels of Nitrotyrosina, an Inflammatory Marker 
Generated by Nitric Oxide Derived Oxidants, Is 
Associated With Risk of Coronary Artery Disease 
Mehdi H. Shishehbor, Ronnier J. Aviles, Marie-L”& Brennan, Xiaoming Fu, Marc S. 
Penn. Dennis L. Sprecher, Noyan Gokce, John F. Keaney, Jr., Joseph A. Vita, Stanley L. 
Hazen, The Cleveland Clinic Foundation, Cleveland, OH, Boston University School of 
Medicine, Boston, MA 
Background: Formation of nitric oxide (.NO)-derived oxidants may selve as a mechanism 
linking inflammation to development of atherosclerosis. Nitrotyrosine. a specific marker 
for protein modification by .NO-derived oxidants. is enriched in human atherosclerotic 
lesions and LDL recovered from human atheroma. Whether systemic levels of nitroty- 
rosine predict coronary artery disease (CAD) is not known. 
Methods: Serum nitrotyrosine levels in 262 consecutive patients at a major metropolitan 
medical center were determined by mass spectrometry and correlated with the preva- 
lence of CAD. 
Results: The median nitrotyrosine content of plasma proteins was significantly higher in 
the CAD group (9.13 umoVmol vs. 5.66 umol/mol, P c 0.001). Subjects in the upper quar- 
tile of nitrotyrosine levels had higher risk of CAD (unadjusted odds ratio, 4.06; 95% confi- 
dence interval, 1.94 to 8.50; P < 0.001). After adjusting for Framingham risk factors and 
high sensitive C-reactive protein, upper quartiles of nitrotyrosine remained predictive for 
CAD risk (odds ratio, 3.01; 95% confidence interval, 1.26 to 7.07; P < 0.001). 
Conclusion: Elevated levels of nitrotyrosine, a specific protein modification produced by 
.NO-derived oxidants and which is linked to CAD pathogenesis, serves as a significant 
and independent predictor of CAD risk. These results support a potential role for .NO- 
derived oxidants as an inflammatory mediator in CAD and may have important implica- 
tions for atherosclerosis diagnosis and risk assessment, 
“T 1st 2nd-~ 3rd 4th 
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857-l Incidence and Characteristics of Ruptured Plaque in 
Femoro-Poplitaal Arteries 
Yoichiro Honaq Ali Hassan, Krishnankutty Sudhir. Daniel Adelman, Yasuhiro Honda, 
Paul G. Yock, Peter J. Fitzgerald, Stanford University, Stanford, CA, Pharmacyclics Inc., 
Sunnyvale, CA 
Background: Numerous studies have reported the characteristics of atherosclerotic 
lesions with plaque rupture in coronary arteries. However the incidence and characteris- 
tics of plaque rupture in the peripheral circulation have not been well studied. 
Methods: Ninety-seven lesions in 40 patients scheduled for elective angloplasty in either 
the femoral or popliteal arteries were enrolled. IVUS was performed before intervention. 
Lesion inclusion criteria were: (1) segmental, (2) proximal reference % plaque area < 
50%, (3) degree of calcified arc < 90”. Discontinuity of luminal sulfate with a cavity within 
the plaque mass was defined as plaque rupture. Lumen area, vessel area, degree of cal- 
cified arc. plaque eccentricity index (El) and remodeling index (RI: lesion I proximal refer- 
ence vessel area) were measured. 
Results: Plaque rupture was observed in 42 lesions (43%). When lesions with and with- 
out plaque rupture were compared, lumen area, degree of calcified arc and El were iden- 
tical (6.9k3.7 vs.6.9+5.2m& 22+25 vs.25+31’, 0.74*0.16 vs.O.73*0.16, NS). However, 
vessel area and RI were significantly higher in lesion with plaque rupture (30.1*6.0 
vs.26.0*6.9mm? p=O.OOl. 1.09+0.19 vs.O.98+0.16, p=O.OOS). The distribution of remod- 
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cling types (positive, intermediate and negative) was also different in lesions with and 
wthout plaque rupture. 
Conclusion: In the femoro-popliteal circulation, the appearance of plaque rupture is 
common (43%) and is highly associated wth positive remodeling. 
2:15 pm. 
857-2 Hospital Volume and Mortality in Acute Aortic 
Dissection: Does Low Volume Predict Worse Outcome? 
Salil J. Patel, Rajendra H. Mehta, Linda Pape, Stuart Hutchinson, Dean E. Smith, Jeanna 
V. Cooper, Pat O’Gara, Toru Suzuki, Eric M. Isselbacher, Christoph A. Nienaber, Kim A. 
Eagle, University of Michigan, Ann Arbor, MI 
Background: Acute Aortic Dissection (AAD) is associated with a very high mortality. 
Studies have shown an increased mortality at low volume centers in coronary artery 
bypass and/or valve surgery. However, to our knowledge, no studies have assessed this 
relation in AAD. To characterize whether hospital volume correlates with mortality, we 
examined outcomes data in a large cohori of patients with AAD. 
Methods: We evaluated 962 patients enrolled in the International Registry of Aortic Dis- 
section (IRAD) between l/1996 and 10/2001. Data from 15 centers in 7 countries were 
included. Linear regression analysis was performed correlating mortality and annual hos- 
pital volume. Centers were grouped and analyzed into teriiles based on AAD’volume. 
Data between low and higher volume centers was compared using a Chi-square test. 
Further adjustment for morbidity was made by means of multivariate prediction models 
for predicted death both for proximal and distal AAD, creating an overall observed versus 
expected mortality risk for each hospital. 
Results: The number of AAD cases per hospital per year ranged from 4 to 34. Overall 
hospital mortality for AAD was 25%. Mortality rates for all AAD were not significantly dif- 
ferent between lowest volume and higher volume hospitals (p=O.27). Similarly, there 
were no significant differences in death between low and high volume centers for Type A 
dissection or Type A dissections managed surgically. While there was a trend for lower 
mortality in Type B dissection in higher volume centers (p=O.O45), the confidence limits 
surrounding the point estimate were wide. 
Conclusions: AAD continues to be associated with high in-hospital mortality rates. Our 
data, reflecting cases reported over recent years, did not show a convincing difference 
between volume and outcome for AAD, despite a large population of patients collected 
by multiple centers. Risk adjustment indicated that lower volume centers did not perform 
more poorly than higher volume institutions. It may be that volume of overall heart sur- 
gery, or perhaps aortic. aortic valve, or a combination of surgical procedures proves to be 
more improtant in determining mortality in AAD, not simply the number of AAD alone. 
2:30 p.m. 
857-3 The Effects of Exercise on Lower Extremity Functioning 
in Peripheral Arterial Disease Patients Without 
Intermittent Claudication: A Randomized Controlled 
Clinical Trial 
Mary M. McDermott Susan D. Tiukinhoy, Ty Gluckman, Shay Unterreiner, William H. 
Pearce, Michael H. Criqui, Kiang Liu, Jack M. Guralnik, Philip Greenland. Northwestern 
University Feinberg School of Medicine, Chicago, IL 
BACKGROUND: Most patients with lower extremity peripheral arlerial disease (PAD) do 
not have classical symptoms of intermlttent claudication (IC). We hypothesized that 
supervised exercise training would improve leg functioning in patients with PAD who do 
not have IC. METHODS: PAD subjects were identified from a non-invasive vascular lab- 
oratory at an academic medical center. Those without IC were included. Subjects were 
randomly assigned to a supervised treadmill exercise intervention vs. usual care. Exer- 
cise occurred 3 times weekly for 12 weeks for up to 60 minutes each session. The six- 
minute walk test was our primary outcome. We also measured fastest pace walkmg 
speed over 4 meters. We used intentlon to treat analyses. Of 35 enrolled, 26 completed 
baseline and follow-up testing. Of these, 54% had no exertional leg symptoms and 46% 
had exertional lea svmotoms other than IC. The table shows chanaes between baseline I , 
and follow-up. The Intervention group had a significant increase in B-minute walk pedor- 
mance between baseline and follow-uo fo=O.O2). CONCLUSION: Walkino endurance 
improved after a supervised exercise program in PAD patients without IC. If these find- 
ings are confirmed in a larger cohort, exercise may prove to have important effects on 
functional performance in PAD patients without IC. 
Changes in Lower Extremity Functianmg m Response lo Exercise 
Exercise Group (n=l6) Control group @IO) P Value 
6-minute walk (feet) 132.0 (124) 46.2 (216) 0.265 
Fast 4-meter walk (m/se@ 0.003 (0.16) -0.053 (0.14) 0.402 
2:45 p.m. 
857-4 Effects of Avasimibe in Claudicants With Peripheral 
Arterial Disease 
Willlam R. Hiatt, Ellen Klepack, Mark Nehler, James Imus, Judith Regensteiner, Michael 
Criqui, University of Colorado Health Sciences Center, Denver, CO, Pfizer Global 
Research and Development, Ann Arbor, Ml 
Background: Avasimibe. an Inhibitor of acyl coenzyme A-cholesterol acyltransferase 
(ACAT), was assessed for symptomatic improvement in moderate to severe claudication. 
Methods: Patients with chronic, stable, claudicatlon symptoms secondary to PAD 
(ankle-brachial index s 0.90 at rest with a 20% reduction post-exercise) were enrolled. 
Primary endpoint, change from baseline in absolute claudication distance (ACD) com- 
pared to placebo after 52 weeks of treatment of avasimlbe 50 mg, 250 mg, or 750 mg 
daily using a graded treadmill protocol (2 mph, 2% grade every 2 minutes). 
Results: TreadmIll results are shown in the table. Avasimibe 50 mg, although not statisti- 
cally significant after adjusting for multiple comparisons, demonstrated the greatest 
improvement in ACD compared to placebo (difference = 0.76 min, p=O.O27). This finding 
was supported by change in initial claudicatlon distance (ICD) (difference = 0.5 min, 
p=O.O26) and walking distance as measured by the Walking Impairment Questionnaire 
(WIQ) (difference = 5.5%, p=O.O56). 
Conclusion: The observed increase in ACD at the 50 mg dose, although not statlstically 
significant, may suggest a symptomatic benefit with chronic oral avasimibe in claudica- 
tion. 
Least-Squares Mean Change in Time to ACD From Baseline at Week 52, Mean (SE) 
Time to ACD (minutes) Placebo Avasimibe 
50 mg 250 mg 750 mg 
N 92 90 101 90 
Change’ 0.66 (0.26) 1.42 (0.26)’ 0.96 (0.25) 0.63 (0.26) 
N=number of patients 
’ ANCOVA model 
* P=O.O27 (P<O.O245 required for statistical significance) 
3:oo p.m. 
857-5 Cilostazol in Raynaud s Disease: A Double-Blind 
Placebo Controlled Clinical Trial 
San~av Rawao~alan, Dana Pfenninger, Christine Kehrer, Emily Somers, Anjan 
Chakraborti, William J. McCune, Debabrata Mukherjee, Robert D Brook, Mariana 
Kaplan, Uwersity of Michigan, Ann Arbor, Ml 
Background: Raynaud’s syndrome (RS) is characterized by recurrent episodes of 
vasospasm occuring in isolation (primary l.RS) or in association with rheumatologic 
states (secondary, 2.RS). We investigated the effect of the phosphodiesterase Ill inhibl- 
tor cllostazol I” this disorder. 
Methods: Subjects with moderate-severe RS were stratified by diagnosis (1 or 2.RS) 
and randomized to receive placebo or cilostazol 100 mglday bid for 6 weeks in a double- 
blind manner. Brachial artery vasoreactivity to assess conduit vessel function, laser Dop- 
pler fluxmetry to assess microvascular flow, and cold pressor testing (CPT) were per- 
formed at study entry and exit. Symptoms were assessed throughout the B-week 
duration using validated attack scores. 
Results: A total of 19 patients with 1 .RS and 21 patients with 2.RS matched for age, vas- 
cular risk factors, and symptom severity completed the study. Cilostazol, but not placebo, 
resulted in an increase in brachial artery diameter at 6 weeks, with a 16% and 17% 
increase in 1 .RS and 2.RS, respectively (P co.05 for both). There was no change in 
median flow-mediated dilation (FMD) (4.06 [25!“-7ti” percentile, 2.5-6.11 to -0.77 l-2.42. 
3.451) in 1 ii or Pii RS (2.23 [0.05 to 6.271 to 2.95 [1.69 to 7.41). Nitroglycerin-mediated 
dilation, microvascular flow indices, and symptom severity were unchanged in both 
cohorts. Cilostazol in l.RS, but not in 2.RS, resulted in a positive change in the slope of 
brachial responsiveness to CPT, which translated to an increase of 0.32 mmlmin com- 
pared with placebo (P = 0.002). Cilostazol treatment remained significantly associated 
with increased brachial artery diameter when controlled for body mass index, age, cho- 
lesterol, triglycerides, cholesterol/high-density lipoprotein ratio, and systolic blood pres- 
sure (P= 0.018). 
Conclusion: Cilostazol increases conduit vessel diameter in RS. There was a favorable 
Impact on conduit vessel responsiveness to cold in 1 .RS without impacting microvascular 
flow or symptoms at 6 weeks. A longer duration of treatment or higher doses may be 
required to see a benefit in these parameters in RS. These results provide Important 
Insights for designing future pharmacotherapeutic interventions in RS. 
3:15 p.m. 
857-6 A Prospective Case-Control Study of Tobacco 
Dependence in Thromboangiitis Obliterans (Buerger s 
Disease) 
Leslie T. Cooper, Stavonnie S. Henderson, Kenneth P. Offord. Tak Sun Tse, David R. 
Holmes, Richard D. Hurt, Mayo Clinic and Foundation, Rochester, MN 
Background: Thromboangiitis Obliterans (TAO) is often cited as an extreme phenotype of 
vasculopathy and tobacco dependence. Although tobacco exposure IS essential to pro- 
gression of arterial ischemia in TAO, expert opinion differs regarding the degree of 
tobacco dependence in this population. We designed a prospective, case-control study 
